Compare · QTRX vs RVTY
QTRX vs RVTY
Side-by-side comparison of Quanterix Corporation (QTRX) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both QTRX and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $17.26B, about 118.9x QTRX ($145.2M).
- RVTY has been more active in the news (7 items in the past 4 weeks vs 6 for QTRX).
- RVTY has more recent analyst coverage (23 ratings vs 13 for QTRX).
- Company
- Quanterix Corporation
- Revvity Inc.
- Price
- -
- -
- Market cap
- $145.2M
- $17.26B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 6
- 7
- Recent ratings
- 13
- 23
Quanterix Corporation
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Latest QTRX
- SEC Form 4 filed by Quanterix Corporation
- Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals
- Director Magovcevic-Liebisch Ivana converted options into 4,224 shares, increasing direct ownership by 36% to 15,883 units (SEC Form 4)
- Director Mendel Scott was granted 4,398 shares, increasing direct ownership by 18% to 28,454 units (SEC Form 4)
- Director Donnelly William P was granted 6,964 shares, increasing direct ownership by 4% to 169,365 units (SEC Form 4)
- Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026
- SEC Form 4 filed by Chief Commercial Officer Gute James Edward Jr.
- Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Chief Technology Officer Miller Michael Francis converted options into 1,558 shares and covered exercise/tax liability with 467 shares, increasing direct ownership by 3% to 38,452 units (SEC Form 4)
- Quanterix Names Dr. Yuri Fesko Chief Medical Officer
Latest RVTY
- Revvity to Present at Upcoming Investor Conferences
- William Blair initiated coverage on Revvity
- Revvity to Host Investor Day
- VP and CAO Gonzales Anita sold $13,060 worth of shares (84 units at $155.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)
- Revvity to Hold Earnings Call on November 3, 2026
- Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
- Officer Krakowiak Maxwell sold $235,728 worth of shares (1,631 units at $144.53) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 14,781 units (SEC Form 4)
- Officer Vohra Tajinder S sold $1,032,650 worth of shares (7,330 units at $140.88) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 6,635 units (SEC Form 4)
- UBS resumed coverage on Revvity with a new price target
- Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery